{"organizations": [], "uuid": "a288f4a024ed5c0c2ac9201f27ab5b0d6281ebad", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180529.html", "section_title": "Archive News &amp; Video for Tuesday, 29 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/shire-ma-takeda/shareholders-demand-japans-takeda-assuage-fears-over-shire-deal-idUSL3N1T03JP", "country": "US", "domain_rank": 408, "title": "CORRECTED-OFFICIAL-Shareholders demand Japan's Takeda assuage fears over Shire deal", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-29T18:31:00.000+03:00", "replies_count": 0, "uuid": "a288f4a024ed5c0c2ac9201f27ab5b0d6281ebad"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/shire-ma-takeda/shareholders-demand-japans-takeda-assuage-fears-over-shire-deal-idUSL3N1T03JP", "ord_in_thread": 0, "title": "CORRECTED-OFFICIAL-Shareholders demand Japan's Takeda assuage fears over Shire deal", "locations": [], "entities": {"persons": [{"name": "takeda", "sentiment": "negative"}], "locations": [{"name": "japan", "sentiment": "none"}, {"name": "tokyo", "sentiment": "none"}], "organizations": [{"name": "shire", "sentiment": "negative"}, {"name": "takeda", "sentiment": "negative"}, {"name": "takeda pharmaceutical co ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Takeda spokesman corrects comment on number of votes needed for proposal to pass to two thirds from half in 3rd paragraph)\nTOKYO, May 29 (Reuters) - Japanese drugmaker Takeda Pharmaceutical Co Ltd faces demands from disgruntled shareholders to put to a vote its $62-billion acquisition of London-listed Shire and do more to assuage concerns over the record-breaking deal.\nThe deal “carries overly high risks to the company”, 12 shareholders said in a proposal to be voted on at next month’s annual meeting of shareholders, adding that new shares to be issued to fund the deal threaten “a danger of causing a great disadvantage to existing shareholders”.\nThe Shire deal and any future deals worth more than 1 trillion yen ($9.19 billion) should be put to a shareholder vote, says the proposal - which will need two thirds of the votes at the meeting to pass, according to a Takeda spokesman.\nTakeda’s board of directors opposes the proposal, according to the company’s notice of convocation that contained the proposal.\nThe drugmaker already plans to put the Shire deal to a vote at an extraordinary general meeting. ($1=108.8300 yen) (Reporting by Sam Nussey; Editing by Clarence Fernandez/Adrian Croft)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-29T18:31:00.000+03:00", "crawled": "2018-05-30T21:14:01.028+03:00", "highlightTitle": ""}